Background: Leucorrhoea and associated symptoms, such as pruritus and pain, significantly impact women's reproductive health and quality of life. This study evaluates the efficacy of a test drug compared to a standard drug in managing these symptoms. Objectives: To assess the impact of treatment on pain severity, pruritus, and quality of life using subjective parameters and validated scales, such as the 5D Pruritus Score. Methods: A comparative study was conducted with patients divided into test and control groups. Pain severity was measured using the Visual Analog Scale (VAS), and pruritus was assessed through pruritus severity grading and the 5D score. Paired and independent t-tests were employed to analyze intra- and intergroup differences. Results: Both the groups demonstrated significant reductions in low back and lower abdominal pain (p < 0.0001), though no significant difference was observed between the groups. The study revealed significant reductions in dyspareunia and dysuria in both groups (p < 0.0001), with a notable difference in dysuria severity between the test and control groups post-treatment (p = 0.032). Finally, the study found a significant improvements in pruritus severity and 5D score in both groups (p < 0.0001), with a significant difference between the test and control groups after treatment (p = 0.0038). Overall, the test group showed greater improvements, especially in pruritus severity and 5D score. Conclusion: The test drug performed excellently well in managing pain and pruritus, as demonstrated by significant reductions in symptom severity and improved quality of life parameters. These findings underscore the potential of the test drug as an effective therapeutic option, warranting further investigation and clinical application.